The adage 'do more with less' is of increasing relevance to global economies, with governments under pressure to cut and compress public spend yet simultaneously increase both productivity and
The EMA's human medicines committee has recommended against approval of Eisai and Biogen's Alzheimer's disease therapy Leqembi, after regulators in the US, China and Japan gave a green ligh